The Zacks Analyst Blog Highlights: Roche, Danaher, BlackRock, Kinder Morgan and Allstate
For Immediate Release
Chicago, IL – April 24, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Roche RHHBY, Danaher DHR, BlackRock BLK, Kinder Morgan KMI and Allstate ALL.
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports on Roche, Danaher and BlackRock
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche, Danaher and BlackRock. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Buy-ranked Roche’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry in the past six months, gaining +10.5% vs. a decline of -1.0%. The Zacks analyst thinks Roche posted strong sales for the first quarter of 2019, propelled by demand for new drugs amid biosimilar competition for legacy drugs. Consequently, the company raised its guidance for the year.
Strong performance of Ocrevus, Perjeta, Tecentriq and Hemlibra offset lower sales of MabThera/Rituxan. In particular, MS drug Ocrevus witnessed strong growth, driven by increased demand. Also, label expansion of Tecentriq into various indications contributed to first-quarter sales.
Meanwhile, the company is looking to restructure its portfolio beyond oncology into MS and haemophilia, among others. Roche dominates the breast cancer space with strong demand for its HER2 franchise drugs.
Shares of Danaher have gained +19.7% over the past three months, outperforming the Zacks Diversified Operations industry, which has increased +16.5% over the same period. In first-quarter of 2019, the company’s earnings and sales beat estimates.
The Zacks analyst thinks sturdier demand for innovative products, effective Danaher Business System (“DBS”) implementation and shareholder-friendly policies will likely bolster profitability going forward. Also, it anticipates that the acquisition of General Electric Company’s BioPharma business will complement its biologics workflow solutions of the Life Sciences segment. The divestiture of its dental business will boost its competency.
However, rising cost of sales and unfavorable movements in foreign currencies might continue to restrict Danaher’s growth. For 2019, the company lowered adjusted earnings per share guidance, primarily reflecting dilutive impact of funds raised for the BioPharma buyout.
BlackRock’s shares have gained +22.5% in the past six months, outperforming the Zacks Investment Management industry’s increase of +15.5% during the same period. The company’s earnings surpassed expectations in three of the trailing four quarters.
The Zacks analyst thinks its first-quarter 2019 results benefited from lower expenses and higher assets under management (AUM), partly offset by lower revenues. The company’s initiatives to restructure its actively managed equity business, and expand globally via acquisitions to further boost top line and AUM remain impressive.
While a steady increase in operating expenses and high dependence on overseas revenues remain matters of concern, the company’s capital deployment actions reflect strong balance sheet position.
Other noteworthy reports we are featuring today include Kinder Morgan and Allstate.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Danaher Corporation (DHR) : Free Stock Analysis Report
BlackRock, Inc. (BLK) : Free Stock Analysis Report
The Allstate Corporation (ALL) : Free Stock Analysis Report
Kinder Morgan, Inc. (KMI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
